All Clinical Trials

Clinical Trial NCT03817320

T2017-002, A TACL Phase 1/2 Study of PO Ixazomib in Combination with Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

  • ClinicalTrials.gov ID: NCT03817320
  • Recruiting participants (Starts Apr. 1, 2019)
  • Not accepting healthy volunteers
  • UTSW Principal Investigator: HOLLY LYNN PACENTA

summary

Please refer to Sections 10.1, 10.1.1, 10.1.2, and 10.2 of the protocol.

objective

Please refer to Sections 1.0, 1.1, 1.3, 2.0, and 2.1 of the protocol.

If you are interested in this clinical trial, please contact Cris Molina on the Children’s Health Research Team.Call 214-456-6167Email